Cybernic treatment with wearable cyborg Hybrid Assistive Limb (HAL) improves ambulatory function in patients with slowly progressive rare neuromuscular diseases: a multicentre, randomised, controlled crossover trial for efficacy and safety (NCY-3001)

Takashi Nakajima1*, Yoshiyuki Sankai2,20, Shinjiro Takata3, Yoko Kobayashi4, Yoshiiho Ando5, Masanori Nakagawa6, Tosho Saito7, Kayoko Saito8, Chiho Ishida9, Akira Tamaoka10, Takako Saotome4, Tetsuo Ikai11, Hisako Endo1, Kazuiho Ishii10, Mitsuya Morita5, Takashi Maeno6, Kiyonobu Komai9, Tetsuhiho Ikeda1, Yuka Ishikawa12, Shinichiro Maeshima13, Masashi Aoki14, Michiya Ito15, Tatsuya Mima16, Toshihiko Miura17, Jun Matsuda18, Yumiko Kawaguchi19, Tomohiro Hayashi20, Masahiro Shingu20 and Hiroaki Kawamoto20,21

Abstract

Background: Rare neuromuscular diseases such as spinal muscular atrophy, spinal bulbar muscular atrophy, muscular dystrophy, Charcot-Marie-Tooth disease, distal myopathy, sporadic inclusion body myositis, congenital myopathy, and amyotrophic lateral sclerosis lead to incurable amyotrophy and consequent loss of ambulation. Thus far, no therapeutic approaches have been successful in recovering the ambulatory ability. Thus, the aim of this trial was to evaluate the efficacy and safety of cybernic treatment with a wearable cyborg Hybrid Assistive Limb (HAL, Lower Limb Type) in improving the ambulatory function in those patients.

Results: We conducted an open-label, randomised, controlled crossover trial to test HAL at nine hospitals between March 6, 2013 and August 8, 2014. Eligible patients were older than 18 years and had a diagnosis of neuromuscular disease as specified above. They were unable to walk for 10 m independently and had neither respiratory failure nor rapid deterioration in gait. The primary endpoint was the distance passed during a two-minute walk test (2MWT). The secondary endpoints were walking speed, cadence, and step length during the 10-m walk test (10MWT), muscle strength by manual muscle testing (MMT), and a series of functional measures. Adverse events and failures/problems/ errors with HAL were also evaluated. Thirty patients were randomly assigned to groups A or B, with each group of 15
Background

To perform voluntary movements, humans need motor intention, which is transmitted via signals from the brain through the nervous system, and finally to effector muscles. In 1928, Sherrington used the term ‘motor unit’ for the complex of a lower motor neuron and the muscle fibres innervated by its axon [1]. For voluntary movements, the motor units are controlled by descending tracts of the central nervous system. There are a number of diseases that impair voluntary movements, and can occur at specific sites from the central nervous system to the motor unit. Previous studies, such as Ramón y Cajal [2], showed that in animal models, damaged neurons in the central nervous system (CNS) did not regenerate and synapses did not reconnect. Therefore, it has been thought that, in contrast to peripheral lesions, lesions of the CNS (including motor neurones) are permanent and cannot be regenerated even by rehabilitation. Hence, most rehabilitation programs for patients with motor impairment have not directly aimed to restore the function but rather only used the residual function to acquire compensatory activities [3].

Neuromuscular diseases are a broadly-defined group of disorders that involve injury to or dysfunction of the motor unit [4]. Especially in degenerative neuromuscular diseases, which are mainly caused by rare genetic variations, it has been considered that no therapeutic process is effective unless the underlying cause is removed at an early stage, owing to the dogma established by early on by studies such as that of Ramón y Cajal [2]. In these neuromuscular diseases, any treatment has been considered unlikely to be effective when advanced muscle atrophy and bone and joint deformities reach a progressed state. These progressive neuromuscular diseases are associated with a constant loss of the residual function and the difficulty in regaining compensatory activities. Moreover, excessive exercise conducted to improve the motor function has been known to lead to a further functional decline [5, 6]. Therapies that include muscle strength training and endurance training in neuromuscular diseases remain controversial [7–11]. Hence, exercise therapy to restore the motor function has been considered dangerous and is not a common method of recovering function in these patients. For these reasons, there is a notable lack of safe and effective exercise programs for patients with neuromuscular diseases.

Therefore, until recently, only curative treatments based on the aetiology of neuromuscular diseases have attracted attention. Nevertheless, it has been shown that aetiologically-based treatments do not provide sufficient functional improvement in progressive neuromuscular diseases. For example, nusinersen—an antisense oligonucleotide—has been clinically tested for the treatment of spinal muscular atrophy (SMA), which is caused by a deficiency in the survival motor neuron (SMN) protein; the results showed that the effect of the treatment diminished as the disease progressed [12]. Furthermore, although leuprolrelin—which inhibits the nuclear transport of testosterone and the abnormal androgen receptor—has been clinically demonstrated to improve dysphagia in patients with bulbar spinal muscular atrophy (SBMA), there was no improvement in the ambulatory function [13]. While muscle biopsies in patients undergoing exon skip therapy to target the dystrophin gene with eteplirsen demonstrated the desired effect on protein synthesis in patients with the fatal neuromuscular disorder Duchenne muscular dystrophy (DMD), no sufficient relevant motor improvement was observed [14, 15]. Thus, even if drug developments are aetiologically successful, it is considered highly unlikely that lower motor neurons will re-innervate the muscle fibres and that the central nervous system will also regain control over the motor unit, including lower motor neuron. Therefore, the development of therapeutics that promote neuromuscular reconnection or remodulation has become an important research goal.

A member of our team, Dr Yoshiyuki Sankai, pioneered the innovative academic field known as ‘cybernics’, or the fusion of humans, robots, and information systems. Dr Sankai invented the wearable cyborg Hybrid Assistive
Limb (HAL) based on the principle of cybernics [16–20]. Cybernics technology links the human nervous system and a robot through bioelectric signals such as motor unit potentials, which results in a dynamic state in which the wearer and HAL are functionally and physically connected. HAL functions in accordance with the motor intention of the wearer and internal ideal movement patterns as if it were a part of the body. The process that realizes the fusion of a human and HAL via the mutual exchange of neural information (e.g., motor unit potentials and proprioception) and dynamic mechanical information (e.g., coordinates, velocity, and angular velocity in limb segments) between the wearer's nervous system and HAL was named “interactive biofeedback (iBF)” by Dr Sankai. Since its inception, HAL has been implemented into the society (e.g., HAL lumbar type for labour support in the workplace) as well as the medical field as the world’s first cyborg-type robot [21].

Despite visual similarities, HAL is completely different from other exoskeletal robots [22, 23], which are not cybernics based. These non-cybernic exoskeletal robots repeat mechanical patterns or are under the physical control of the wearer. In the case of HAL, the wearer performs voluntary movements, in which the neuromuscular and central nervous systems work to produce the intended movement of the integrated HAL and the wearer’s body. HAL is synchronized with the intention to move in accordance with the motor unit potentials produced by a command from the CNS. In this way, the iBF loop is created between the wearer and HAL [18, 24–30] as follows: [brain→spinal cord→motor nerves→(HAL + musculoskeletal system)] and [HAL→musculoskeletal system→sensory nerves→spinal cord→brain]. Using HAL, this loop can be easily repeated without increasing the neuromuscular system’s excessive load and fatigue. The physician or operator can intervene in this transmission loop by tuning the parameters embedded in HAL. Furthermore, it is believed that the return of sensory signals from the proprioceptors in the muscles, joints, and skin to the CNS is of great importance for neuroregeneration [31, 32].

In the present study, we propose that cybernics (i.e., the iBF created by the union of HAL and the nervous and musculoskeletal systems of the wearer) enables the regeneration of the impaired motor function. This neuroplasticity [33] would result in the reconnection of the CNS to the motor units [34] and the reconnection of motor neurons to muscle fibres. Thus, we hypothesized that the strengthening and adjusting of the synaptic connections in the neuromuscular and central nervous systems can be achieved via the iBF loop and may therefore result in neuroregeneration and regaining of the motor function, i.e., motor learning. At the beginning, we planned two clinical trials (RCTs) to assess the efficacy of iBF in neuroregeneration [30, 35, 36]; (1) NCY-2001, an RCT conducted to confirm whether iBF can induce neuroplasticity in case of the lesions of the CNS (i.e., lesions of the brain and spinal cord, located above the level of the motor units; spastic paraplegia), and (2) NCY-3001, an RCT conducted to confirm whether iBF is effective when motor units are damaged. When motor units are damaged, HAL needs to effectively detect weak and sparse motor unit potentials and compensate for very weak muscle power. Considering that HAL for medical use (lower limb type), which was originally developed for neuromuscular diseases, could also be helpful in a wider range of diseases and levels of progression (e.g., acute spinal cord injury and cerebrovascular disease to chronic disease), and given the lack of therapeutics that promote neuroregeneration, we sought to test the efficacy of HAL (NCY-3001) first in cases of slowly progressive rare neuromuscular diseases in which motor units were damaged (e.g., SMA, SBMA, muscular dystrophy, Charcot-Marie Tooth disease [CMT], distal myopathy, sporadic inclusion body myositis, congenital myopathy, and amyotrophic lateral sclerosis [ALS]).

**Methods**

**Study design and patients**

The NCY-3001 clinical trial constitutes an open-label, multicentre, randomised, controlled trial, using a crossover design to evaluate the safety and efficacy of an intermittent cybernic treatment with HAL to improve the gait function in patients with neuromuscular diseases. A crossover design was used to reduce the required sample size, which was an important issue because the target diseases are very rare. A requirement for the crossover design is that the symptoms of the disease (e.g., gait impairment) are stable over the time period of the study. To facilitate the recruitment of patients, the trial was conducted at nine clinical sites in Japan between March 6, 2013, and August 8, 2014. The general eligibility criteria were as follows: age ≥ 18 years; diagnosis confirmed based on diagnostic criteria for SMA, SBMA, ALS, muscular dystrophy, CMT, distal myopathy, sporadic inclusion body myositis, or congenital myopathy; no rapid changes in gait symptoms for three months prior to the start of the trial; an inability to walk 10 m independently without the use of an assistive device such as a cane or a walker. Eligible patients were further screened with the following exclusion criteria: exercise limitations owing to cardiac and/or respiratory failure; skeletal deformities such as osteoarthritis of the hip, knee, or spine, and scoliosis; severe osteoporosis; severe tendency to bleed; reliance on a ventilator; serious hepatic or renal...
disorder; incurable neoplasm. The following criteria specific to the use of HAL were also evaluated: body weight 40–100 kg; height 150–190 cm; healthy skin for the placement of the electrodes; ability to move the hip and knee joints using the cybernic voluntary control (CVC) mode of HAL; generation of a ground reaction force of sufficient magnitude to be detected by the HAL shoe sensors. Initiation or discontinuation of a new gait rehabilitation program, systemic administration of steroids, and administration of riluzole, sodium valproate, or any drug intended to inhibit the progression of the target disease for which HAL was being evaluated was not permitted within two months of the pre-observation period of the trial and throughout the study period.

Randomisation and masking
The trial consisted of a four-week pre-observation period, two treatment blocks of 13 weeks each, and a four-week post-observation period. At the end of the pre-observation period, during which eligibility was assessed, the eligible patients were randomised (1:1) to either group A or B. The groups differed in the sequence of the treatments received: for group A, a control walking program with hoist only (treatment 1) was followed by a walking program with hoist and HAL (treatment 2). For group B, treatment 2 was followed by treatment 1 (Fig. 1). The patients were randomised using a web-based allocation system, with stratification for sex, age (< 65 and ≥ 65 years), and disease (SMA/distal myopathy and ‘other’ diagnoses). All the individuals were assigned numerical designations as site number-subject number (Table 1). While this was an open-label trial, individuals who performed the visual gait assessment were blinded to group allocation and patient- and disease-related characteristics.

Investigational device
HAL-HN01 (Cyberdyne Inc., Tsukuba, Japan) is an investigational device distributed in the EU under the name HAL-ML05 and has received ISO13485 and CE0197 approval as the first robotic treatment medical device. HAL-HN01 was invented by one of the authors, Dr Yoshiyuki Sankai, for the recovery of gait in patients with neuromuscular diseases. HAL-HN01 is an upgrade to the previous HAL models and has an improved capacity to detect the low magnitude and sparse motor unit potentials through the skin of patients with neuromuscular disease.

Detailed device specifications for HAL-HN01 are available in the package insert and operation manual. Briefly, HAL-HN01 weighs approximately 15 kg and consists of an exoskeletal frame for the femurs, lower legs, and waist, two motor power units for each leg driven by a lithium-ion battery on the hip and knee joints in order to assist flexion and extension, a back module, a controller, and sensor shoes that measure the gait phase. There are two electrodes for each direction of joint movement and one reference electrode. In total, nine electrodes are necessary for each leg to detect the motor unit potentials on the surface of the wearer’s skin. The hybrid mechanism that enables the integration of mechanical assistance and the wearer’s power for his/her own voluntary movement is incorporated within the HAL system using three control mechanisms: CVC, cybernic autonomous control (CAC), and cybernic impedance control (CIC). In CVC, the assisting torque controls movement based on bioelectrical signal intensity. Bioelectric signals (BES) are motor unit potentials on the skin; they correspond to the motor torque required for each joint movement, including hip and knee, in accordance with the wearer’s motor intention. In CAC, assistance for pre-programmed leg movement patterns is provided, and these are available for

![Fig. 1](image-url)
each type of ideal movements (standing up to maintaining the standing position, and maintaining the standing position to walking) and serve as a guide to achieving the ideal movement pattern of the connected limbs of the wearer and HAL. In CIC, outputs corresponding to joint movements (impedance control) are provided. As a result, the wearers do not feel the additional weight of HAL or change in the moment of inertia and are able to perceive the position and movement of their legs with their own proprioception. Both CIC and CAC are always activated. The expected walking speed is input by the operator to adapt the CAC support to the gait cycle changes according to the walking speed. In the CVC, the electrodeposition, BES sensitivity, signal processing filter, and balance between the extensor and flexor assist torque are adjusted by the operator at the beginning of the gait exercise so that the wearer can walk naturally and comfortably with HAL.

All members of the medical staff, including medical doctors, physiotherapists, occupational therapists, nurses, and clinical assistants who operate the HAL-HN01 system are required to complete an education program (minimum of four hours), including a certification examination by Cyberdyne Inc. to ensure a safe use of HAL-HN01.

### Procedures and cybernic treatment

After providing informed consent, eligible patients were enrolled into the pre-observation period of the trial (Fig. 1), during which the patients wore HAL-HN01 to

| Characteristic | Group A (N = 13) | Group B (N = 11) |
|---------------|-----------------|-----------------|
| Age (years)   | 56.0 (13.2)     | 55.5 (7.8)      |
| < 65          | 10 (76.9%)      | 9 (81.8%)       |
| ≥ 65          | 3 (23.1%)       | 2 (18.2%)       |
| Female sex    | 6 (46.2%)       | 6 (54.5%)       |
| Height (m)    | 1.642 (0.085)   | 1.643 (0.099)   |
| Weight (kg)   | 54.97 (9.16)    | 59.15 (14.67)   |
| Body mass index (kg/m²) | 20.38 (2.85) | 21.67 (3.89) |
| Blood pressure (mm Hg) | 128.7 (8.5)/84.7 (13.6) | 118.2 (15.6) / 72.9 (10.0) |
| Heart rate (beats/min) | 75.0 (9.3) | 75.6 (8.0) |
| Abnormal ECG  | 4 (30.8%)       | 5 (45.5%)       |
| Other neurological abnormal findings | 0 (0%) | 0 (0%) |
| Muscle CT findings consistent with the target disease | 13 (100%) | 11 (100%) |
| Previous diseases | 0 | 0 |
| Concurrent diseases | 12 (92.3%) | 9 (81.8%) |
| Number of targeted neuromuscular diseases | | |
| Spinal muscular atrophy | 3 | 2 |
| Spinal bulbar muscular atrophy | 2 | 0 |
| Amyotrophic lateral sclerosis | 1 | 0 |
| Charcot Marie Tooth disease | 1 | 2 |
| Myotonic dystrophy | 0 | 2 |
| Distal myopathy with RV | 0 | 1 |
| Distal myopathy, Myoshi | 2 | 2 |
| FSH-type muscular dystrophy | 2 | 1 |
| Other limb girdle-type muscular dystrophy | 1 | 1 |
| Sporadic inclusion body myositis | 1 | 0 |
| Concomitant treatment, medication | 13 (100%) | 11 (100%) |
| Other rehabilitation programs | 9 (69.2%) | 8 (72.7%) |
| Outpatient during treatment periods | 8 (61.5%) | 2 (18.2%) |
| 2MWT (metres) | 63.258 (30.457) | 67.257 (25.508) |
| Barthel index (total score: 0–100) | 75.4 (21.0) | 84.5 (11.9) |
| Total Manual Muscle Test (MMT) scores (0–60) | 31.12 (5.57) | 30.59 (3.64) |

*Data are means (SD) or numbers (%); SD, standard deviation; RV and FSH denote Rimmed Vacuole and Facioscapulohumeral, respectively.*
ensure proper functioning of the CVC and shoe sensors and were subsequently randomised to group A or B.

Treatment 1 (conventional control treatment) consisted of a 40-min walking session using only a dedicated hoist (All in One®, Ropox A/S, Denmark) (Fig. 2A). The hoist was used for safety, to prevent falls, and to facilitate the provision of any gait assistance needed by the medical staff. A single walking session comprised warming up, 20 to 30 min of walking exercise depending on the patient’s condition, a brief rest, and a period of cooling down. Treatment 2 (cybernic treatment intervention) also consisted of a 40-min walking session using a hoist, with HAL-HN01 applied to the lower limbs (Fig. 2B). For both the treatments 1 and 2, the patients in groups A and B completed the sessions in nine visits (days), up to four visits per week, over a 13-week allowance period. The alternate treatment of either treatment 2 or 1 was then completed (Fig. 1). A transfer period, from one to 3 weeks, was scheduled between the treatments 1 and 2 to prevent any interference between the treatments’ efficacies and adverse effects. At the end of this period, there was a 4-week post-observation period to observe the persistence of clinical efficacy and the occurrence of adverse events after treatment. The treatment efficacy was evaluated as the change rate in the measured outcomes as follows: from the first to the final session of treatment 1 (i.e., Visit V4 and V13 for group A and V14 and V23 for group B), and from the first to the final session of treatment 2 (i.e., V14 and V23 for group A, and V4 and V13 for group B), as well as to the final session of the post-observation period (i.e., V24 for both groups).

Outcome measures

Ambulatory function was evaluated using two standardized outcome measures: the 2-min walk test (2MWT) [37] and the 10-m walk test (10MWT) [38]. The 2MWT evaluates the maximum gait distance (metres) a patient can walk around the dedicated track circuit using the hoist for 2 min. As the 2MWT reflects both walking speed and endurance over 2 min, it was considered to be an appropriate primary endpoint to evaluate the efficacy of the cybernic treatment. The 10MWT was used to evaluate the secondary endpoints of gait speed (m/s), cadence (steps/s), and step length (m), as patients walked as fast as possible using the hoist. To evaluate the subjective effects of exercise therapy, including adverse effects, on gait improvement and to assess the impact of overwork in patients with neuromuscular diseases, a patient-reported outcome (PRO) measure of a feeling of gait was used as another secondary endpoint to evaluate five subjective perceptions: a sense of fatigue when walking, the lightness of foot when walking, a sense of stability when walking, a feeling of safety when walking, and a feeling of pleasure when walking. Each perception was quantified using a visual analogue scale (0 to 100, from worst to best) and added up for a total PRO score. The score of a sense of fatigue was subtracted from 100 to match the meaning of the other items. A retrospective pre-test that compared the previous state (V4 then and V14 then) to the present (V13 and V23, respectively), as well as pre- and post-tests (V13–V4 for the first period, V23–V14 for the second period) were performed. A visual gait analysis was performed using the video recording of the 2MWT.

Fig. 2 Photographs showing the use of mobile hoist and HAL-HN01 in control and cybernic treatments. A Control treatment (treatment 1), patient in hoist only. B Cybernic treatment (treatment 2), patient in hoist + wearing HAL.
and 10MWT to provide a quantitative evaluation of changes in stance and swing gait patterns using the modified Rivermead Visual Gait Assessment [39]. The total value was calculated by evaluating the deterioration and improvement (i.e., changes) on a 7-point Likert scale (−3 to +3) for 16 items of stance and swing phases. Manual muscle testing (MMT) [40], ordinal scale (0–5) of each muscle group, is a standardized set of assessments that measure muscle strength and function. Twelve MMT scores of each lower limb (bilateral flexion and extension of hip, knee, and ankle) were summed as total MMT score (0–60). The Barthel index, the standardized functional scale (0–100), was used to evaluate activities of daily living (ADL) [41]. A 12-lead electrocardiogram was used to evaluate the cardiac response to the walk exercise load. Pulse rate and blood pressure were also monitored. All adverse events and reactions were qualitatively recorded.

A three-point scale (1 = easy to use, 2 = intermediate, 3 = difficult to use) was evaluated by the operator to assess six criteria (general operability of HAL, preparation, putting on HAL, walking, taking off HAL, and maintenance). The time from attaching the electrode to the completion of putting on HAL was measured at the 5th, 7th, and 9th sessions of HAL. The safety of the device was also evaluated in terms of failure and by a review of the error history saved in the HAL system.

**Statistical analysis**

The target sample size was 30 subjects (15 subjects per group). Previous clinical unpublished data indicate that the use of HAL for Well-Being (the non-medical model), which is the first HAL model without medical insurance coverage which can be used for disabled people in Japanese regulations, resulted in a clinically significant improvement (mean ± standard deviation, 28.5% ± 21.5) in gait speed and distance. Assuming no improvement in treatment 1 (hoist only), the sample size required to detect an intergroup difference (significance level, 0.05; power, 0.90) in a parallel group design would be 12 subjects per group. Typically, the required sample size for a crossover design is less than half of that of a parallel group design [42]. Nevertheless, we did not reduce the number of cases to allow for stratified allocation and to evaluate the device’s safety.

The efficacy of the cybernic treatment in terms of the primary endpoint (2MWT) was evaluated by an independent evaluator according to the predefined statistical analysis plan for the trial, as per ICH E-9 guidelines. The full analysis set (FAS) used in the intention-to-treat analysis included the data from all randomised patients except those for whom a complete assessment of the primary endpoint was not performed at the end of both treatment periods (Fig. 1). The data for these patients were not included, as there was no adequate guideline for missing data in the crossover design. Data in the FAS that violated important inclusion criteria or exclusion criteria, which would have affected the results of the evaluation of the primary endpoint, were excluded from the “per protocol set” (PPS). The “all subjects as treated set” (ASaT) included data from patients who wore HAL-HN01 at least once during the study period, including the pre-observation period.

The numbers of subjects who were eligible, declined, and discontinued according to the study protocol, together with the corresponding reasons, are shown in the overview of the trial (Fig. 3).

Demographic data (age, sex, body weight, and height) and baseline values (disease diagnosis, Barthel index score, and MMT) are summarised by group in Table 1 for comparison. The mean and standard deviation were calculated for continuous variables, while ratios were calculated for the between-group comparison of categorical values.

Between-group differences were evaluated using two-tailed t tests for continuous variables, a Mann–Whitney U test for ordinal-scale variables, and Fisher’s exact test for nominal variables. A p value lower than 0.05 was considered significant. The treatment efficacy for the primary endpoint was evaluated using a two-sample t test to compare group A and group B in the crossover design [42]. First, the improvement effect (−dA or dB) was calculated as a difference (i.e., percent change from baseline) between the values for the first and second treatment periods, where baseline was V4 for group A and V14 for group B. Hence, dA or dB was defined as (treatment 1 − treatment 2) in group A, and (treatment 2 − treatment 1) in group B, respectively. Reversing the sign of the values in group A was needed to indicate its HAL improvement effect. A significant treatment effect (−(dA − dB)/2) in the primary endpoint was defined as the difference between group A (dA) and group B (dB) according to the cross-over analysis method [42]. A half of the difference between groups A and B was the actual HAL effect in the cross-over comparison. It indicated the therapeutic efficacy of the cybernic treatment with HAL-HN01. We also assumed that the measured treatment effect would be comparable for each group, indicating that the effect of the intervention was independent (the carryover effect) and stable regardless of the order of the treatments 1 and 2 (the period effect). Therefore, the period effect ((dA + dB)/2) and the carryover effect, which should not be significant, were also calculated to check this assumption [42].

Pre-planned secondary analyses, pre- and post-evaluation using one-sample t test for continuous variables
or Wilcoxon signed-rank test for ordinal-scale variables and the intergroup evaluation of all the endpoints were carried out for the first period (V13–V4), the first and second periods (V23–V4), and for all periods, including the post-observational period (V24–V4). In those analyses, the parallel-group comparisons between treatment 1 (hoist only) and treatment 2 (HAL) were included using the first period (V13–V4) of group A and B to check for the robustness of the results in the crossover design. All statistical analyses were performed using SAS ver. 9.3 (SAS Institute; Cary, NC, USA) in Windows 7.

**Results**

Of the 33 patients who provided written informed consent, two were ineligible at the time of registration to the pre-observation period (Fig. 3). The evaluation of safety was conducted in the remaining 31 patients. One patient was withdrawn from the trial during the pre-observation period, leaving 30 eligible patients at the second time point of registration. After randomisation, six patients were excluded for the following reasons: in group A, one patient voluntarily withdrew from the trial prior to the last 2MWT during the treatment period, and one patient was excluded because of an unmet 2MWT; in group B, one patient withdrew from the trial before the last 2MWT owing to pneumonia, one was excluded owing to an unmet 2MWT, and two discontinued the trial prior to the last 2MWT owing to the investigators’ judgment that it was too difficult for these subjects to continue the trial. Therefore, for the analysis of the FAS, group A consisted of 13 patients and group B consisted of 11 patients. The PPS was identical to the FAS.

The distribution of patient-related characteristics and baseline measures is summarised in Table 1. Individual patient profiles of baseline characteristics are also shown in Table 2. The groups were well balanced in the majority of relevant factors, except that group A had a higher number of patients with an outpatient status during the
The baseline measures for the primary endpoint of 2MWT, Barthel index, and total MMT score were also comparable between the groups (Tables 1 and 2).

For the FAS, the 2MWT data for 24 individuals are shown in Fig. 3. Patients in Fig. 4 are displayed in order of the magnitude of the effect of the treatment 2 (HAL). A treatment effect of HAL over the control treatment effect was observed in 13 subjects (upward stripe bar). A pre/post effect of the treatment 2 (HAL) was observed in 18 subjects (upward black bar). Six patients (6-1*, 6-2*, 5-3*, 2-2, 7-2*, 5-3*) with the negative effect (downward black bar) of the treatment 2 (HAL) were all the outpatients in the group A. While HAL was not effective in these six patients, four of them (6-1*, 6-2*, 1-4*, 5-1*) obtained sufficient improvement with the treatment 1 (hoist only) before starting the treatment 2 (HAL). The crossover analyses using the FAS are summarised in Table 3. The carryover and period effects were not significant ($p = 0.331$ and $p = 0.051$, respectively), thereby confirming the validity of the assumptions in the crossover design.

Regarding other endpoints, the percent changes in speed at 10MWT were substantial but not statistically significant ($p = 0.059$), while step length was not significantly different. Barthel index score, PRO total score (post–pre), PRO total score (post–then), and response shift total score (pre–then) exhibited no significant improvement in the treatment 2 (HAL) compared with the treatment 1 (hoist only) in the crossover design.

In the parallel group comparisons (V13–V4) between groups A and B in the first period (Table 4), the distance for 2MWT ($15.577\%$, $p = 0.044$) and cadence ($8.474\%$, $p = 0.026$) were significantly higher in treatment 2 (HAL) compared with group B ($p < 0.047$). The baseline measures for the primary endpoint of 2MWT, Barthel index, and total MMT score were also comparable between the groups (Tables 1 and 2).

The patient ID indicates site number-patient number. An asterisk (*) in a patient’s ID indicates the outpatient status during the study period.

### Table 2: Individual patient profiles of baseline characteristics

| Targeted neuromuscular diseases | Patient ID | Group | Age (years) | Barthel Index (0–100) | 2MWT (m) | Total MMT scores (0–60) |
|--------------------------------|------------|-------|-------------|-----------------------|----------|------------------------|
| Spinal muscular atrophy        | 1-3        | A     | 52          | 95                    | 116.3    | 35                     |
|                                | 6-1*       | A     | 48          | 100                   | 97.3     | 37                     |
|                                | 6-2*       | A     | 57          | 90                    | 66.5     | 30                     |
|                                | 1-1        | B     | 59          | 85                    | 39.3     | 33                     |
|                                | 9-6        | B     | 57          | 60                    | 68.6     | 28                     |
| Spinal bulbar muscular atrophy | 1-2        | A     | 64          | 80                    | 41.9     | 36                     |
|                                | 5-1*       | A     | 54          | 60                    | 30.1     | 39                     |
| Amyotrophic lateral sclerosis  | 3-2        | A     | 69          | 25                    | 30.3     | 26                     |
| Charcot Marie Tooth disease    | 9-3        | A     | 76          | 95                    | 120.1    | 39                     |
|                                | 8-1        | B     | 55          | 95                    | 55.3     | 31                     |
|                                | 8-2        | B     | 63          | 85                    | 126.5    | 37                     |
| Myotonic dystrophy             | 9-2        | B     | 65          | 90                    | 75.3     | 32                     |
|                                | 9-4        | B     | 51          | 90                    | 90.4     | 28                     |
| Distal myopathy with RV        | 2-3*       | B     | 40          | 100                   | 87.7     | 24                     |
| Distal myopathy, Myoshi        | 2-4*       | A     | 50          | 80                    | 78.3     | 23                     |
|                                | 5-3*       | A     | 63          | 65                    | 25.0     | 31                     |
|                                | 2-2        | B     | 58          | 90                    | 85.2     | 30                     |
|                                | 7-2*       | B     | 47          | 85                    | 59.7     | 36                     |
| FSH-type muscular dystrophy    | 1-4*       | A     | 40          | 90                    | 56.8     | 37                     |
|                                | 2-7        | A     | 46          | 75                    | 57.3     | 29                     |
|                                | 2-6        | B     | 51          | 85                    | 79.1     | 31                     |
| Other limb girdle-type muscular dystrophy | 2-5* | A | 33 | 55 | 97.1 | 26 |
|                                | 9-7        | B     | 65          | 65                    | 48.3     | 29                     |
| Sporadic inclusion body myositis | 3-1*       | A     | 76          | 65                    | 61.7     | 34                     |

The patient ID indicates site number-patient number. An asterisk (*) in a patient’s ID indicates the outpatient status during the study period.
compared with treatment 1 (hoist only). Moreover, in the post-/pre-evaluations in the first period, 2MWT distance, gait speed, cadence, step length, and total MMT score were significantly higher only in treatment 2. In V23–V4 (first + second treatment periods, Fig. 1, Table 4), the 2MWT distance, speed, cadence, and step length exhibited significant changes in comparison to the post-/pre-evaluation of both groups A and B. In this comparison, total MMT score showed significant changes only in group B. In V23–V4 (first + second treatment periods), the 2MWT distance for group A was significantly lower than that of group B (Table 4). The aforementioned trends lasted until the post-observational period in a manner comparable to that of all periods. The PRO total score exhibited significant changes in comparison to post/pre and post/then in the first period.
Table 4  Changes in primary and secondary endpoints over the course of the study periods

|                                      | Treatment 1 in Group A (Control) | Treatment 2 in Group B (HAL) | Treatment 2 vs. Treatment 1 Group A | Treatment 2 vs. Treatment 1 Group B |
|--------------------------------------|----------------------------------|------------------------------|-------------------------------------|-------------------------------------|
|                                      | N=13                             | N=11                         | N=11                               | N=11                               |
|                                      | Mean (95% CI)                    | Mean (95% CI)                | Mean (95% CI)                       | Mean (95% CI)                       |
| 2MWT Distance                        | 9.297 (−0.153, 0.053)            | 24.874 (11.439, 38.309)      | 0.021                              | 15.577 (0.494, 30.660)              |
| 10MWT Speed                          | 7.706 (−1.327, 0.088)            | 19.366 (8.870, 29.863)       | 0.002                              | 11.660 (−1.304, 24.624)             |
| 10MWT Cadence                       | 28.02 (−2.928, 0.308)            | 11.276 (6.221, 16.331)       | 0.0006                             | 8.474 (1.127, 15.820)               |
| 10MWT Step length                    | 4.555 (−0.717, 0.084)            | 7.163 (0.228, 14.098)        | 0.044                              | 2.607 (−5.451, 10.666)              |
| Visual gait assessment total score   | −0.462 SD (3.126) n/a            | 1.000 SD (1.483) n/a         | 0.17                               | 1.462 (0.676, 3.599)                |
| MMT total score                      | 0.23 (−1.46, 1.92) 0.844†        | 1.77 (0.34, 3.20) 0.016†     | 1.54 (−0.603, 0.68) 0.150†         | 0.77 (−0.31, 1.85) 0.191†           |
| Barthel index score                  | 1.2 (−0.2, 2.5) 0.250†           | 1.4 (−0.8, 3.5) 0.500†       | 0.2 (−2.125) 0.902†                | 1.5 (−0.4, 3.4) 0.250†              |
| PRO total score (Post–Pre)           | 101.6 (4.2, 199.0) 0.042          | 890 (1.95, 158.5) 0.017      | −12.6 (−129.9, 104.6)              | 128.5 (30.6, 226.5) 0.014            |
| PRO total score (Post–Then)          | 80.2 (3.1, 157.4) 0.042           | 1074 (30.2, 184.5) 0.011     | 27.1 (−76.5, 130.8)                | 211.9 (46.9, 196.9) 0.005            |

All periods (V23–V4)

|                                      | Group A (Control + HAL) N=12 | p value* | Group B (HAL + Control) N=11 | p value* | Group A vs. Group B N=12,11 | p value** |
|--------------------------------------|------------------------------|----------|------------------------------|----------|-----------------------------|----------|
|                                      | Mean (95% CI)                |          | Mean (95% CI)                |          | Mean (95% CI)                |          |
| 2MWT Distance                        | 12.534 (−3.505, 28.573)      | 0.113    | 35.594 (1.276, 59.911)       | 0.0086   | −23.059 (−49.924, 3.805)    | 0.089    |
| 10MWT Speed                          | 18.180 (−0.853, 37.212)      | 0.060    | 27.429 (1.360, 41.699)       | 0.0016   | −9.250 (−31.967, 13.467)    | 0.407    |
| 10MWT Cadence                       | 9.190 (−2.3335, 20.714)      | 0.107    | 11.04 (6.9550, 15.125)       | 0.0001   | −1.850 (−13.813, 10.113)    | 0.751    |
| 10MWT Step length                    | 7.486 (−0.235, 15.206)       | 0.056    | 14.680 (0.060, 26.301)       | 0.0183   | −7.195 (−20.065, 5.675)     | 0.258    |
| Visual gait assessment total score   | −0.46 (−1.29, 2.22)          | 0.605†   | 205 (0.36, 3.73)             | 0.027†   | −1.58 (−3.91, 0.74)         | 0.171††  |
| MMT total score                      | 1.5 (−0.4, 3.4)              | 0.250†   | 0.9 (−0.4, 2.3)              | 0.500†   | 0.6 (−1.7, 2.9)             | 0.743††  |
| PRO total score (Post–Pre)           |                              |          |                              |          |                              |          |
Table 4 (continued)

| All periods (V24–V4) | p value* | Group B (HAL + Control) | p value* | Group A vs. Group B | p value** |
|----------------------|----------|--------------------------|----------|---------------------|-----------|
| Group A (Control + HAL) | N = 12   | Group B (HAL + Control) | N = 11   |                     |           |
| Mean (95% CI)        |          | Mean (95% CI)           |          | Mean (95% CI)      |           |

PRO total score (Post–then)

* p value was calculated using a one-sample t test or † Wilcoxon signed-rank test
** p value was calculated using a two-sample t test or †† Mann–Whitney U test

SD, standard deviation; CI, Confidence Interval; 2MWT, two-minute walk test; 10MWT, ten-metre walk test; MMT, manual muscle test; PRO, patient-reported outcome
period and the first + second periods (Table 4). However, there was no significant difference in PRO between treatments 1 and 2 in the first period. The Barthel index showed no significant changes in comparing the post/pre evaluation and between groups in the first, first + second, or all periods.

For the 5th use of HAL-HN01 and later, the three point evaluation score improved significantly in comparison to both first time use in overall and all six criteria (Table 5). The response "difficult to use" was not found after the 7th use of HAL-HN01. The time taken to put on HAL at the 5th use had an average value of 323.5 s, a median of 233.5 s, a minimum of 110 s, and a maximum 1200 s, and exhibited a wide degree of variation between clinical sites. While the time taken to put on HAL tended to decrease each time, the differences were not significant.

Safety analyses were performed for all 31 subjects included in the ASaT analysis (Fig. 3). In one subject who wore HAL once only during the pre-observation period, no adverse event or device failure occurred. In the 30 randomised patients (Fig. 3), adverse events occurred in 55.2% (16/29 subjects, 31 events) in treatment 1 (hoist only) and in 80.0% (24/30 subjects, 42 events) in treatment 2 (HAL). There was no significant difference \( p = 0.0539 \), Fisher’s exact test in total adverse event’s frequency between treatments 1 and 2. The incidence rate of adverse events associated with the use of HAL was 46.7% (14/30 patients), and a total of 19 HAL-related adverse events were recorded, mostly in treatment 2 (Table 6). All the adverse events were mild and were easily remedied. Of the adverse events, pain (myalgia, back pain, arthralgia, pain in extremity, as well as arthrosis deformans pain) associated with walking programs accounted for approximately a half of all recorded adverse events. Contact dermatitis, excoriation, erythema, and skin exfoliation were common owing to contact with electrodes and cuffs of HAL. Falls and contusions occurred when HAL was not in use, but they were reported by an investigator to be related to the HAL-HN01 because they happened during the treatment 2 period. In addition, there were no adverse events associated with a failure of the device.

The summary technical document containing the aforementioned data has been successfully reviewed by the PMDA. HAL-HN01 has been approved as a new medical device (approved number: 22700BZX00366000, November 25, 2015) by the Ministry of Health, Labour, and Welfare and is covered by general health insurance in Japan for the treatment of patients with neuromuscular diseases.

Discussion
The present RCT sought to evaluate the cybernics treatment’s efficacy and safety to improve the ambulatory function in eight rare neuromuscular diseases. The crossover analysis confirmed a significant effect of the cybernic treatment on the primary endpoint measure (2MWT), which showed a 10.066% increase compared with the control treatment (hoist only). The results of this trial confirmed that patients with ambulatory dysfunction owing to neuromuscular diseases can achieve significant improvement in the gait function by performing at least nine 40-min sessions of intermittent cybernic treatment with HAL-HN01.

The eligible participants were enrolled into the pre-observation period of the trial and randomised into one of the two groups, so FAS was determined (Fig. 3). In the case of the crossover design (Fig. 1), there are no statistical methods to properly complement the missing values. Therefore, it was appropriate to exclude subjects with partial completion of the 2MWT by the pre-defined criteria of FAS (Fig. 3). Groups A and B were balanced regarding all the baseline measures except for the outpatient status during treatment (Table 1). Eight subjects from group A underwent the trial as outpatients. As six of eight subjects exhibited a higher therapeutic effect of the control treatment than the HAL treatment (Fig. 4), we determined that the effect of treatment with HAL was not overestimated. There were no influences of baseline characteristics on the crossover analyses of treatment effects for groups A and B (Table 1).

Our study showed that the 2MWT was an appropriate indicator of ambulatory capacity in patients with neuromuscular diseases. While previous studies often used the six-minute walk test (6MWT) to assess the submaximal capacity for functional walking that is necessary for ADL across different disease states [37], the 2MWT can reduce high inter-test variability related to fluctuating motivation observed with the 6MWT and is a valid alternative to the 6MWT [37]. The 2MWT has been able to eliminate the problem of extreme muscle fatigue following 6MWT for subjects with neuromuscular diseases [5, 6].

As neuromuscular diseases are both progressive and incurable, and as aetiologically-based drugs for neuromuscular diseases have not been shown to stimulate neuromuscular reconnection or remodulation, our results demonstrating the successful intervention of cybernic treatment are truly ground-breaking [36]. The data for secondary endpoints in the present study demonstrated that cybernic treatment significantly improved cadence. Since we did not observe a significant change in walking speed, cybernic treatment may have alternatively influenced walking endurance as indicated by 2MWT.
In addition, we also consider the significant improvement in the total MMT score after cybernic treatment to be groundbreaking. The present results dispel the notion that the use of HAL for neuromuscular diseases might be also an excessive and dangerous exercise therapy [5, 6]. Thus, to the best of our knowledge, HAL is the very first intervention to improve MMT in cases of neuromuscular disease [43]. Furthermore, we also observed substantial improvements in walking patterns in a visual gait analysis although differences were not significant. As ADL measured by the Barthel index did not significantly improve after nine cybernic treatments in this trial, further trials should investigate whether ADL can be improved by increasing the number of cybernic treatments. In addition, the PRO total scores did not significantly improve during our trial. As PRO scores were subjectively evaluated, recording these values at each of the four-time points, i.e., pre and post in the first and second periods in the crossover design, may have exceeded the limits of patients’ subjective measurement capacity. In the first period (V13–V4), parallel comparisons of groups A and B between the control treatment (treatment 1) and HAL (treatment 2) reaffirmed the primary crossover analyses’ robustness. Both the treatment 1 (hoist only) and treatment 2 (HAL) were performed for group A or B in the opposite order in V23–V4. The results showed that starting with the treatment 2 (HAL) first, followed by the control treatment (group B), led to a more significant improvement in 2MWT distance. These data may suggest that if the same number and content of cybernic treatment (HAL) sessions are performed, the earlier the cybernic treatment is given (such as in group B), the better results might be obtained. The PRO improvement effect of both the treatment 1 (hoist only) and 2 (HAL) on post–pre and post-then in the first period (V13–V4), and on post–pre in the first + second period (V24–V4) in group A and B was clearly significant. Excessive exercise therapy for patients with neuromuscular disease has been considered risky in the presence of overwork muscle weakness[5, 6]. Still, both treatment 1 and 2 improved patients’ subjective ratings of the total PRO scores, indicating more comfort while walking, with no deterioration thought to be due to overwork. This may be because patients with neuromuscular diseases but a willingness to walk evaluate the walking exercise with hoist as safe and good, regardless of whether they use HAL or not. It might also indicate the absence of gait exercise in the present standard clinical care for patients with neuromuscular diseases.

| Table 5 | Changes in the time (s) taken to put on HAL from the 5th time of use of HAL-HN01 |
|---------|-----------------------------------------------------------------------------|
| Times of use of HAL-HN01 | 5th | 7th | 9th | 7th–5th | 9th–5th |
| | Mean | median | (SD) | mean | median | (SD) | mean | median | (SD) | mean | median | (SD) | p value | mean | median | (SD) | p value |
| Time to wear HAL (seconds) | 323.5 | 293.3 | (245.3) | 244.5 | 281.0 | (221.5) | −30.2 | 253.5 | (199.7) | −42.5 | 0.1346 |

SD, standard deviation; CI, Confidence Interval; min, minimum; max, maximum

| Table 6 | Incidence of causally-related adverse events during the trial period of the present study |
|---------|----------------------------------------------------------------------------------------------------------|
| Adverse event | Overall patient number = 14 of 30 | Main cause | Incidence % | Events |
| | | Walk program, weight of the device itself | 13.3% | 4 |
| Myalgia | | Contact with the electrodes | 10.0% | 3 |
| Contact dermatitis | | Walk program, contact with the back module | 6.7% | 2 |
| Back pain | | Contact with the cuffs | 6.7% | 2 |
| Excoriation | | Contact with the electrodes | 3.3% | 1 |
| erythema | | Contact with the electrodes | 3.3% | 1 |
| Skin exfoliation | | Walk program | 3.3% | 1 |
| Arthralgia | | Walk program | 3.3% | 1 |
| Arthrosis deformans pain | | Walk program | 3.3% | 1 |
| Pain in extremity | | Walk program | 3.3% | 1 |
| Pain | | Walk program | 3.3% | 1 |
| Fall | | No occurrence in use but causality cannot be denied | 3.3% | 1 |
| Contusion | | No occurrence in use but causality cannot be denied | 3.3% | 1 |
The time needed to put on HAL was approximately 5 min on average, indicating that suiting up with HAL does not pose a substantial burden for patients and operators for clinical use. While the time necessary to put on HAL did not decrease over time, the ease of use steadily improved according to operator evaluations. The 5th time that HAL was worn, the time to put HAL on varied widely from a minimum of 110 s to a maximum of 1200 s, and no further improvements were noted by the 9th time, indicating that sufficient education/training before using HAL is necessary rather than natural learning.

In the present study, cybernic treatment with HAL did not cause serious adverse events or secondary muscle weakness owing to the excessive use of muscles in these patients. Myalgia and arthralgia, which were observed after cybernic treatment in the present study, are common after exercise and are manageable. As a general precaution when using HAL, it is necessary to observe and address the skin conditions that result from contact with electrodes and cuffs. In particular, it is necessary to pay attention to the effects of HAL on the skin in subjects with sensory impairment, as HAL electrodes are common products used for measuring bioelectric signals, such as in electrocardiogram, and there is little room for improvement in the electrodes themselves.

In this trial, we showed that nine cybernic treatments were safe and effective for patients with neuromuscular disease. Since iBF is a method of motor learning, it is generally considered that Hebb’s law can be applied. However, it should be further explored at what point the learning effect of repeated cybernic treatments reaches a plateau. More specifically, it will be necessary to clarify how the number and frequency of treatments affect this learning curve. Observational studies to this end have already begun [44].

In order to elucidate the principle of effects of cybernic treatment, the underlying mechanisms of iBF should be examined for each component involved in locomotor function. The important components that control locomotor function include the skeletal system, motor unit, proprioceptive system, spinal locomotor central pattern generator [45], and other components of the central nervous system. The reactivation of the spinal locomotor central pattern generator will need to be investigated, as a mere repetitive walking exercise may not activate this centre.

It will be necessary to show proper motor innervation of muscle fibres when examining motor units following cybernic treatment. Stable walking under a variety of conditions requires the CNS to function based on voluntary motor intention [31, 32]. Therefore, it will be necessary to examine the reconnectivity between the CNS and motor units (i.e. neuroplasticity) [34] and to noninvasively elucidate the mechanisms responsible for improvements observed with the cybernic treatment [46]. We believe that the combined cybernic treatment with nusinersen therapy in SMA, leuprorelin administration in SBMA, and exon skip therapy in DMD would show synergistic effects and further improve the treatment effects compared with each monotherapy.

Even if aetiologically-based treatments, such as antisense nucleotide therapy, are performed several years after the onset of neuromuscular disease, the motor function has been shown not to improve despite improved biomarker levels and no further worsening of symptoms [12, 13]. In this case, aetiologically-based therapies combined with cybernic treatment may have significant pre/post effects.

In the targeted population in this trial, each disease entity is rare, and these patients are vulnerable. We combined eight neuromuscular diseases into a group as neuromuscular diseases that share the same motor unit involvement. This grouping allowed us to perform a randomised controlled study of HAL-HN01 for such patients. The limitations were a short-term trial, the small number of patients with each of the diseases, and the inability to stratify the allocation of patients across all the conditions. Thus, in the future, we would like to conduct an observational study of long-term efficacy and safety in a higher number of patients with each of the diseases.

**Conclusions**

The present study is the first RCT to show the effectiveness and safety of cybernic treatment for neuromuscular disease, and it provides hope for the effective treatment in those living with often debilitating and incurable neuromuscular disorders. This study showed significant improvements in gait function in patients with incurable neuromuscular diseases after nine iBF-based cybernic treatments with HAL-HN01 compared with walking exercises with a hoist only. We believe that the observed clinical effects, which are limited to improvement in gait function and total MMT score, stem from motor learning or functional regeneration by iBF. Cybernic treatment with HAL-HN01 has the potential to become standard treatment for walking impairment in patients with neuromuscular diseases, both with and without aetiologically-based therapies.

Lastly, the efficacy of iBF-based cybernic treatment will be undoubtedly verified by integrating the results of our next trial on spastic paraplegia caused by CNS lesions (NCY-2001) with those of the present study (NCY-3001). We consider that cybernic treatment can be used for a broad range of lesions and aetiologies, including those in the brain, spinal cord, and motor units, from acute to chronic stages [47]. Preliminary
studies have also shown that HAL-HN01 is a useful medical device for improving the motor function. Future RCTs will be needed to prove efficacy and safety in other diseases, such as cerebrovascular disease [48–50], spinal cord injury [51, 52], multiple sclerosis, Parkinson disease, spinocerebellar degeneration, and Guillain–Barre syndrome. Although the present RCT results are limited to only neuromuscular diseases, this study opens the possibility of applying cybernic treatment to other diseases. Our findings set a precedent for replacing existing walking exercise therapy using a hoist or treadmill alone with cybernic treatment using HAL.

Acknowledgements
We thank Dr Makoto Sawaguchi, of Shiga University of Medical Science, for advice on statistical analyses. We thank the other clinical investigators, physiotherapists, and clinical research coordinators at each clinical site. We thank the physiotherapists at Cyberdyne Inc. We thank Ms. Aki Hirayasu, Dr Haruhide Kawabe, and the other members of RCR Co., Ltd. for their outstanding assistance in the GCP compliance of this trial. We thank the members of MetbiX Inc. for managing the clinical data and performing statistical analyses. We thank Ms. Kiyomi Kaneko, Ms. Tamao Makino, Ms. Fujiko Uemura, Ms. Aya Kobayashi, Ms. Fumiyu Murayama, and Ms. Wakahiro Komata for managing the CRC work. We thank Ms. Yoko Inotsume and Ms. Kaori Ohgake for assistance in designing the methods of the cybernic treatment and gait evaluation in a hospital physiotherapy setting. All persons mentioned in the acknowledgements have provided written consent. We also would like to thank Mr. Andrew P. Wood for English language assistance. We also would like to thank Enago (www.enago.com) for the manuscript review and editing support.

Authors’ contributions
TN designed and managed this clinical trial and performed the statistical analyses as a coordinating member and the principal investigator. YS invented and produced HAL-HN01. TN, ST, YKo, YA, MN, TSai, KS, CI, AT, and TSao were principal investigators at the respective clinical sites. Tika, HE, KL, MM, TMae, KK, and Tike were clinical investigators at the respective clinical sites. YL, SM, and TImu are members of the visual gait analysis committee. MN, KS, and MA are clinical advisors for neuromuscular diseases. MI, TImin, and HK are members of the safety and efficacy monitoring committee. JM is an ethical and philosophical adviser. YK is an adviser from a patient advocacy group. TH, MSh, and HK are the technical and safety managers for the HAL-HN01. All authors read and approved the final manuscript.

Funding
This work received support from the “Research on Measures for Intractable Diseases” project, a matching fund subsidy from the Ministry of Health, Labour, and Welfare (MHLW). This research was also partially supported by the Project for Cybernics Research, University of Tsukuba, Tsukuba, Japan. The internal review boards of all clinical sites approved this trial, and the requests. During the current study. Please contact the corresponding author for data requests.

Availability of data and materials
Data sharing is not applicable to this article as no datasets were generated during the current study. Please contact the corresponding author for data requests.

Declarations
Ethics approval and consent to participate
The internal review boards of all clinical sites approved this trial, and the protocol was completely reviewed and approved by the Japanese authority, Pharmaceutical and Medical Devices Agency (PMDA). This trial fully complied with the ordinance for medical device GCP (Good Clinical Practice) and was inspected by the PMDA.

Consent for publication
Not applicable.

Competing interests
TN, ST, MN, TSai, KS, AT, Tika, HE, KL, and Tike report grants from MHLW & AMED, non-financial support such as temporary use of the investigation device, HAL-HN01 from CYBERDYNE Inc., during the conducting of the study. YKo, YA, TSao, CL, TMae, MM, and YKo report grants from MHLW, non-financial support such as temporary use of the investigation device, HAL-HN01 from CYBERDYNE Inc., during the conducting of the study. YL, SM, MA, MI, TImin, TImu, JM, and YKa report grants from MHLW & AMED during the conducting of the study and personal fees from CYBERDYNE Inc. unrelated to the submitted work. MSh and TImu report grants from MHLW & AMED, personal fees from CYBERDYNE Inc., during the conducting of the study, and personal fees from CYBERDYNE Inc. unrelated to the submitted work.

Author details
1 Departments of Neurology and Rehabilitation Medicine, National Hospital Organization Niigata National Hospital, 3-52 Akasaka, Kashiwa, Niigata 945-8585, Japan. 2 Center for Cybermics Research, University of Tsukuba, Tsukuba, Japan. 3 Department of Orthopedics and Rehabilitation, National Hospital Organization Tokushima National Hospital, Yoshinogawa, Japan. 4 Department of Medical Rehabilitation, National Center Hospital, National Center of Neurology and Psychiatry, Kodaira, Japan. 5 Division of Neurology, Department of Internal Medicine, Jichi Medical University, Shimotuke, Japan. 6 Department of Neurology, Kyoto Prefectural University of Medicine, Kyoto, Japan. 7 Division of Child Neurology, Department of Neurology, National Hospital Organization Osaka Toneyama Medical Center, Toyonaka, Japan. 8 Institute of Medical Genetics, Tokyo Women’s Medical University, Shinjuku, Japan. 9 Department of Neurology, National Hospital Organization Iou National Hospital, Kanazawa, Japan. 10 Department of Neurology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan. 11 Department of Rehabilitation, Tokyo Women’s Medical University, Shinjuku, Japan. 12 Department of Pediatric Neurology, National Hospital Organization Hokkaido Medical Center, Sapporo, Japan. 13 Department of Rehabilitation Medicine II, School of Medicine, Fujita Health University, Tsu, Japan. 14 Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Japan. 15 Human Brain Research Center, Kyoto University Graduate School of Medicine, Kyoto, Japan. 16 Department of Rehabilitation, National Hospital Organization Hokkaido Medical Center, Sapporo, Japan. 17 Graduate School of Humanities and Social Sciences, Shizuoka University, Shizuoka, Japan. 18 ALS/MND Support Center Sakura, Nakano, Japan. 19 CYBERDYNE Inc., Tsukuba, Japan. 20 Faculty of Engineering, Information and Systems, University of Tsukuba, Tsukuba, Japan.

Received: 24 May 2021 Accepted: 27 June 2021
Published online: 07 July 2021

References
1. Sherrington CS. Remarks on some aspects of reflex inhibition; 1925.
2. Ramón y Cajal S. Cajal’s degeneration and regeneration of the nervous system Facsimile of the 1928. London, New York: Hafner Publishing Company; 1991.
3. Almli CR, Stanley F. Toward a definition of recovery of function. In: Almli CR, Finger S, LeVere TE, Stein D, editors. Brain injury and recovery: theoretical and controversial issues. New York: Plenum; 1988. p. 1–14.
4. Morrison BM. Neuromuscular diseases. Semin Neurol. 2016;36:409–18.
5. Bennett RL, Knowlton GC. Overwork weakness in partially denervated skeletal muscle. Clin Orthop. 1958;12:22–9.
6. Johnson EW, Braddom R. Over-work weakness in facioscapuloh幽默 muscular dystrophy. Arch Phys Med Rehabil. 1971;52:333–6.
7. Dal Bello-Haas V, Florence JM. Therapeutic exercise for people with amyotrophic lateral sclerosis or motor neuron disease. Cochrane Database Syst Rev. 2013;5:CD005229.
8. Gianola S, Pecoraro V, Lambiase S, Gatti R, Banfi G, Moja L. Efficacy of muscle exercise in patients with muscular dystrophy: a systematic review showing a missed opportunity to improve outcomes. PLoS ONE. 2013;8:e66414.

9. Voet NB, van der Kooi EL, Riphagen I, Lindeman E, van Engelen BG, Geurts AC. Strength training and aerobic exercise training for muscle disease. Cochrane Database Syst Rev. 2013;3:CD003907.

10. Bartels B, Montes J, van der Pol WL, de Groot JF. Physical exercise training for type 3 spinal muscular atrophy. Cochrane Database Syst Rev. 2019;3:CD12120.

11. van der Kooi EL, Lindeman E, Riphagen I. Strength training and aerobic exercise training for muscle disease. Cochrane Database Syst Rev. 2005;1:CD003907.

12. Mercuri E, Darras BT, Chiriboga CA, Day JW, Campbell C, Connolly AM, et al. Nusinersen versus sham control in later-onset spinal muscular atrophy. N Engl J Med. 2018;378:625–33.

13. Hashizume A, Katsuno M, Suzuki K, Barno H, Takeuchi Y, Kawashima M, et al. Efficacy and safety of leuprolrelin acetate for subjects with spinal and bulbar muscular atrophy: pooled analyses of two randomized-controlled trials. J Neurol. 2019;266:1211–21.

14. Randeree L, Estlick GD. Etopilensin for paediatric patients with Duchenne muscular dystrophy: a pooled-analysis. J Clin Neurosci. 2018;49:41–6.

15. Lim KR, Maruyama R, Yokoita T. Etopilensin in the treatment of Duchenne muscular dystrophy. Drug Des DevTher. 2017;11:533–45.

16. Sankai Y, Ohta M, Kumagai Y. An artificial kidney control system based on a cybernetics conception. Artif Organs. 1989;13:359.

17. Sankai Y, Fujikawa W, Watanabe K, Moriyama H. HOJO-brain for motion control of robots and biological systems. Artif Life. 1998;2:162–9.

18. Sankai Y, Ohta M. Therapeutic robot system during hemopurification aimed at human oriented system. In: Proceedings of the IEEE international workshop on intelligent motion control, vol 1; 1990. p. 247–51.

19. Sankai Y. HAL: Hybrid Assistive Limb based on cybernetics. In: Robotic research, The 13th international symposium ISBN: 2010-25-34.

20. Sankai Y, Suzuki K, Hasegawa Y. Cybernetics: fusion of human, machine and information systems. Tokyo: Springer; 2014.

21. Lazarte M. Enter the first cyborg-type robot. ISOfocus. 2014;106:16–21.

22. Alcobendas-Maestro M, Esclain-Ruz A, Casado-Lopez RM, Munoz-Gonzalez A, Perez-Mateos G, Gonzalez-Valdizan E, et al. Lokomat robotic-assisted versus overground walking training within 3 to 6 months of incomplete spinal cord lesion: randomized controlled trial. Neurorehabil Neural Repair. 2012;26:1058–63.

23. Khan AS, Livingstone DC, Hurst CL, Duchcherer J, Misiaszek JE, Gorasini MA, et al. Retraining walking over ground in a powered exoskeleton after spinal cord injury: a prospective cohort study to examine functional gains and neuroplasticity. J Neuroeng Rehabil. 2019;16;145.

24. Hayashi T, Kawamoto H, Sankai Y. Control method of robot suit HAL working as operator’s muscle using biological and dynamical information. In: 2005 IEEE/RSJ international conference on intelligent robots and systems. 2005. p. 3063–68.

25. Kawamoto H, Taal S, Ninis H, Hayashi T, Kamibayashi K, Eguchi K, et al. Voluntary movement support control of Robot Suit HAL triggered by bioelectrical signal for hemiplegia. Conf Proc IEEE Eng Med Biol Soc. 2010;2010:462–6.

26. Kubota S, Nakata Y, Eguchi K, Kawamoto H, Kamibayashi K, Sakane M, et al. Feasibility of rehabilitation training with a newly developed wearable robot for patients with limited mobility. Arch Phys Med Rehabil. 2013;94:1080–7.

27. Tsukahara A, Hasegawa Y, Eguchi K, Sankai Y. Restoration of gait for spinal cord injury patients using HAL with intention estimator for preferable swing speed. IEEE Trans Neural Syst Rehabil Eng. 2015;23:308–18.

28. Sankai Y, Sakurai T. Functional regenerative medicine: the dawn of a Cybernetic Treatment. Regen Med. 2017;16:90–101 (in Japanese).

29. Sankai Y, Sakurai T. Future of cybernetics and treatment of neurological disorders: functional regenerative treatment with HAL. Neurol Med. 2017;86:596–603 (in Japanese).

30. Nakajima T. Applications of cybernetics to treatment of neurological diseases—the future perspectives and suggestions from the experience of the investigator-initiated & GCP-regulated clinical trial of the cyborg type HAL. Neurol Med. 2017;86:583–9 (in Japanese).

31. Bernstein NA. On dexterity and its development. Dexterity and its development 1996:3–23.

32. Kawahira K, Noma T, Iiyama J, Etoh S, Ogata A, Shimozono M. Improvements in limb kinetic apraxia by repetition of a newly designed facilitation exercise in a patient with corticobasal degeneration. Int J Rehabil Res. 2009;32:178–83.

33. Hoisp JA, Luft AR. Cortical plasticity during motor learning and recovery after ischemic stroke. Neural Plast. 2011;2011:871296.

34. Isa T, Kinoshita M, Nishimura Y. Role of direct vs. indirect pathways from the motor cortex to spinal motoneurons in the control of hand dexterity. Front Neurol. 2013;4:191.

35. Nakajima T. Clinical trial of robot suit HAL technology for neuromuscular intractable rare diseases. J Natl Inst Public Health Jpn. 2011;60:130–7 (in Japanese).

36. Nakajima T. Chapter 11, Innovative technology, clinical trials and the subjective evaluation of patients: the cyborg-type robot HAL and the treatment of functional regeneration in patients with rare intractable neuromuscular diseases in Japan. In: Bruck Sch, Sasaki K, editors. Humans & machines in medical contexts—case studies from Japan. London: Palgrave Macmillan; 2021.

37. Andersen LK, Knak KL, Witting N, Vissing J. Two- and 6-minute walk tests assess walking capability equally in neuromuscular diseases. Neurology. 2016;86:442–5.

38. Tyson S, Connell L. The psychometric properties and clinical utility of measures of walking and mobility in neurological conditions: a systematic review. Clin Rehabil. 2009;23:1018–33.

39. Lord SE, Halligan PW, Wade DT. Visual gait analysis: the development of a clinical assessment and scale. Clin Rehabil. 1998;12:107–19.

40. Mendell JR, Florence J. Manual muscle testing. Muscle Nerve. 1990;13(Suppl):S16-20.

41. Saito T, Izawa KI, Matsui N, Arai K, Ando M, Morimoto K, et al. Comparison of the measurement properties of the functional independence and difficulty scale with the Barthel index in community-dwelling elderly people in Japan. Aging Clin Exp Res. 2017;29:273–81.

42. Wellek S, Blettner M. On the proper use of the crossover design in clinical trials: part 18 of a series on evaluation of scientific publications. Dtsch Arztebl Int. 2012;109:276–81.

43. Uchikawa K, Liu M, Hanayama K, Tsuji T, Fujiwara T, Chino N. Functional status and muscle strength in people with Duchenne muscular dystrophy. Arztebl Int. 2012;109:276–81.

44. CYBERDYNE. Longterm outcome survey of “HAL for Medical Use (Lower Limb Type)”, JMA-IA00301 2017. https://dbcentre3.jmacct.med.or.jp/JMACT/app/JMACTRE02_04/JMACTRE02_04.aspx?kbn=3&seqno=6950. Accessed 9 May 2021.

45. Sasada S, Kato K, Kadowaki S, Gross SJ, Ugawa Y, Komiyama T, et al. Volitional walking via upper limb muscle-controlled stimulation of the lumbar locomotor center in man. J Neurol Sci. 2004;236:124–9.

46. Veldhuis A, Borg J, Palmcrantz S. Clinical application of the Hybrid Assistive Limb Type) , JMA-IIA00301 2017. https://dbcentre3.jmacct.med.or.jp/JMACT/app/JMACTRE02_04/JMACTRE02_04.aspx?kbn=3&seqno=6950. Accessed 9 May 2021.

47. Maeda A, Noguchi S, Sasaki N, Sato T, Inoue T, Haga Y, Goshio M, et al. Efficiveness of a walking program involving the Hybrid Assistive Limb robotic exoskeleton suit for improving walking ability in stroke patients: protocol for a randomized controlled trial. JMIR Res Protoc. 2019;8:e14001.

48. Szczesny-Kaiser M, Trost R, Aach M, Schildhauer TA, Schwenkreis P, Tegenthoff M. A randomized and controlled crossover study investigating the improvement of walking and posture functions in chronic stroke patients using HAL exoskeleton—the HALESTRO study (HALexoskeleton STROKE study). Front Neurosci. 2019;13:259.
50. Yokota C, Yamamoto Y, Kamada M, Nakai M, Nishimura K, Ando D, et al. Acute stroke rehabilitation for gait training with cyborg type robot Hybrid Assistive Limb: a pilot study. J Neurol Sci. 2019;404:11–5.
51. Jansen O, Grasmuecke D, Meindl RC, Tegenthoff M, Schwenkreis P, Sczepny-Kaiser M, et al. Hybrid Assistive Limb exoskeleton HAL in the rehabilitation of chronic spinal cord injury: proof of concept; the results in 21 patients. World Neurosurg. 2018;110:e73–8.
52. Okawara H, Sawada T, Matsubayashi K, Sugai K, Tsuji O, Nagoshi N, et al. Gait ability required to achieve therapeutic effect in gait and balance function with the voluntary driven exoskeleton in patients with chronic spinal cord injury: a clinical study. Spinal Cord. 2020;58:520–7.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.